Lack of innovation is the only barrier when it comes to cellular therapies, says Celixir's Ajan Reginald

Ajan Reginald does not dispute the ability of life-saving cellular therapies to reach patients – and backs regulators’ moves to make this happen quicker through conditional approvals.

As chief executive of UK biotech Celixir – formerly known as Cell Therapy Ltd – he is working closely with the world’s major regulators and health technology assessment bodies to ensure that the companies’ tissue-specific regenerative medicines deliver on their promise to save and improve lives.

In terms of the barriers that companies face in making that ambitious vision a reality, Mr Reginald believes that the only real risks are faults with the medicines themselves or in the planning to get them to market.